Individual generic drug information

tenofovir alafenamide

Reference monograph

Part of registered formulation

DOLUTEGRAVIR SODIUM + EMTRICITABINE + TENOFOVIR ALAFENAMIDE

Reference record: Tenofovir alafenamide
Source: BNF 80 (2020–2021)
Printed source pages: 681
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Tenofovir alafenamide only.

Indications And Dose

Chronic hepatitis B (initiated by a specialist) ▶BY MOUTH ▶Adult: 25 mg once daily (for duration of treatment consult product literature)

Source page 681

Cautions

Decompensated liver disease. HIV co-infection

Source page 681

Pre Treatment Screening

Manufacturer advises HIV antibody testing should be offered to those with unknown HIV-1 status before initiation of treatment.

Source page 681

Safety

Extracted information for Tenofovir alafenamide only.

Interactions

→Appendix 1: tenofovir alafenamide

Source page 681

Side Effects

▶Common or very common Abdominal distension. arthralgia . ﬂatulence ▶Frequency not known Hepatitis aggravated (during or following treatment). nephrotoxicity

Source page 681

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

Source page 681

Hepatic Impairment

Manufacturer advises caution in Infection decompensated hepatic disease (no information available).

Source page 681

Monitoring Requirements

Manufacturer advises monitor liver function tests at repeated intervals during treatment and for at least 6 months after last dose— recurrent hepatitis may occur on discontinuation.

Source page 681

Dose and formulations

Extracted information for Tenofovir alafenamide only.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Vemlidy (Gilead Sciences International Ltd) A Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 25 mg Vemlidy 25mg tablets | 30 tablet P £325.73 ANTIVIRALS › NUCLEOTIDE ANALOGUES

Source page 681

Clinical care

Extracted information for Tenofovir alafenamide only.

Patient And Carer Advice

Missed doses Manufacturer advises if a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Source page 681

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

25 mg once daily (for duration of treatment

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 681

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

tenofovir alafenamide

Reference monograph

Part of registered formulation

DOLUTEGRAVIR SODIUM + EMTRICITABINE + TENOFOVIR ALAFENAMIDE

Reference record: Tenofovir alafenamide
Source: BNF 80 (2020–2021)
Printed source pages: 681
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Tenofovir alafenamide only.

Indications And Dose

Chronic hepatitis B (initiated by a specialist) ▶BY MOUTH ▶Adult: 25 mg once daily (for duration of treatment consult product literature)

Source page 681

Cautions

Decompensated liver disease. HIV co-infection

Source page 681

Pre Treatment Screening

Manufacturer advises HIV antibody testing should be offered to those with unknown HIV-1 status before initiation of treatment.

Source page 681

Safety

Extracted information for Tenofovir alafenamide only.

Interactions

→Appendix 1: tenofovir alafenamide

Source page 681

Side Effects

▶Common or very common Abdominal distension. arthralgia . ﬂatulence ▶Frequency not known Hepatitis aggravated (during or following treatment). nephrotoxicity

Source page 681

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

Source page 681

Hepatic Impairment

Manufacturer advises caution in Infection decompensated hepatic disease (no information available).

Source page 681

Monitoring Requirements

Manufacturer advises monitor liver function tests at repeated intervals during treatment and for at least 6 months after last dose— recurrent hepatitis may occur on discontinuation.

Source page 681

Dose and formulations

Extracted information for Tenofovir alafenamide only.

Medicinal Forms

Source page 681

Clinical care

Extracted information for Tenofovir alafenamide only.

Patient And Carer Advice

Missed doses Manufacturer advises if a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Source page 681

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

25 mg once daily (for duration of treatment

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 681

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.